RemeGen reported preliminary FY 2025 results with total revenue of CNY 3.3 billion, up 89.4%. Operating profit was CNY 721.4 million, while net income attributable to shareholders was CNY 708.5 million; net income attributable to shareholders excluding non-recurring items was CNY 65.1 million. Basic earnings per share were CNY 1.29 and weighted average return on net assets was 24.9%. Total assets were CNY 7.2 billion at year-end, up 31.7%, and parent equity was CNY 3.6 billion, up 81.4%; net assets per share were CNY 6.72, up 82.1%. RemeGen said growth was driven by rapidly rising PRC sales of its core products telitacicept and disitamab vedotin, and higher technology licensing revenue after granting Vor Biopharma exclusive rights to develop and commercialize telitacicept worldwide excluding Greater China. The company also cited lower unit production costs, improving gross margins, a lower sales expense ratio, and reduced overseas R&D expenses linked to the telitacicept licensing. It also noted a May 2025 placement of 19,000,000 new H shares at HKD 42.44 per share.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RemeGen Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260227-12032544), on February 27, 2026, and is solely responsible for the information contained therein.
Comments